These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12599590)

  • 1. [Problems of prostate cancer in elderly patients].
    Kato H; Nishizawa O
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():304-8. PubMed ID: 12599590
    [No Abstract]   [Full Text] [Related]  

  • 2. Focal therapy meets prostate cancer.
    Lazzeri M; Guazzoni G
    Lancet; 2010 Sep; 376(9746):1036-7. PubMed ID: 20870082
    [No Abstract]   [Full Text] [Related]  

  • 3. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer--the snowball is rolling.
    Ruutu M; Salo J; Nordling S; Rannikko S
    Ann Chir Gynaecol; 1999; 88(1):5-8. PubMed ID: 10230675
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recent advancement in diagnosis and treatment of prostate cancer--general concepts].
    Akaza H
    Nihon Rinsho; 2005 Feb; 63(2):237-40. PubMed ID: 15714972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
    Egawa S
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():100-6. PubMed ID: 12599553
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?
    Carroll PR
    J Urol; 2005 Apr; 173(4):1061-2. PubMed ID: 15758699
    [No Abstract]   [Full Text] [Related]  

  • 9. Continued undertreatment of older men with localized prostate cancer.
    Carter HB
    Urology; 2004 Jul; 64(1):189-90; author reply 190. PubMed ID: 15245976
    [No Abstract]   [Full Text] [Related]  

  • 10. [Summary and characteristics of 'General rule for clinical and pathological studies on prostate cancer (the 3rd edition)'].
    Murai M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():39-43. PubMed ID: 12599542
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prostate carcinoma: prostate-specific antigen--and then what?].
    Schmid HP
    Ther Umsch; 1998 Jul; 55(7):426-8. PubMed ID: 9702110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management].
    Malmström PU
    Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565
    [No Abstract]   [Full Text] [Related]  

  • 14. [The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].
    Kimura G; Kimata R; Saito Y; Yoshida K; Nishimura T
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():479-85. PubMed ID: 12599623
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Ansari MS
    J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
    [No Abstract]   [Full Text] [Related]  

  • 16. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer recurrence fear: the prostate-specific antigen bounce.
    Balmer LL; Greco KE
    Clin J Oncol Nurs; 2004 Aug; 8(4):361-6. PubMed ID: 15354922
    [No Abstract]   [Full Text] [Related]  

  • 18. A rational approach to prostate cancer.
    Kirk D
    Practitioner; 2000 Sep; 244(1614):750, 754-6, 758 passim. PubMed ID: 11048371
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 20. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.